SCHEMBL2097524

SCHEMBL2097524

CC(NC1CC[N]C1)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
POLB P06746 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ATM Q13315 1/20 0.44
LMNA P02545 3/20 0.40
EPHX1 P07099 2/20 0.40
TAAR1 Q96RJ0 2/20 0.40
RECQL P46063 1/20 0.40
CYP2D6 P10635 3/20 0.38
ALPL P05186 1/20 0.37
ALPI P09923 1/20 0.37
ALPG P10696 1/20 0.37
HPGD P15428 1/20 0.35
KDM1A O60341 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CHRM2 P08172 1/20 0.35
HTR1A P08908 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27818229 0.80 GAA (0.85) GAAL3MBTL1POLBMEN1KMT2A
SCHEMBL664938 0.80 GAA (0.85) GAAL3MBTL1POLBMEN1KMT2A
SCHEMBL3668041 0.77 GAA (1.00) GAAL3MBTL1POLBMEN1KMT2A
SCHEMBL2093243 0.76 MGAM (0.43)
SCHEMBL2092719 0.76 MGAM (0.43)
SCHEMBL3034097 0.76 GAA (0.36) GAAL3MBTL1CYP2D6
SCHEMBL3665297 0.75 GAA (0.96) GAAL3MBTL1POLBMEN1KMT2A
SCHEMBL21104687 0.75 GAA (0.96) GAAL3MBTL1POLBMEN1KMT2A
SCHEMBL3671016 0.75 GAA (0.96) GAAL3MBTL1POLBMEN1KMT2A
SCHEMBL28091017 0.75 GAA (0.96) GAAL3MBTL1POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1631570-A1 NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS Abbott Laboratories (US) 2006-03-08 EP claimed
WO-2004083207-A1 NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS ABBOTT LABORATORIES (US) 2004-09-30 WO claimed
US-20030232818-A1 Antibacterial compounds ABBVIE INC. 2003-12-18 US claimed
US-8163769-B2 1,8-naphthyridine derivatives ABBOTT LABORATORIES (US) 2012-04-24 US disclosed
EP-1631570-A1 NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS Abbott Laboratories (US) 2006-03-08 EP disclosed
WO-2004083207-A1 NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS ABBOTT LABORATORIES (US) 2004-09-30 WO disclosed
US-20030232818-A1 Antibacterial compounds ABBVIE INC. 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232818-A1 Antibacterial compounds PGLS, UGT1A1, CASP1 GAA 240/4885L3MBTL1 1277/4885POLB 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.